[Skip to Content]
[Skip to Content Landing]
Views 3,248
Citations 0
Invited Commentary
July 1, 2019

Treatment of Fatty Liver Disease—Time to Implement Common Sense Measures

Author Affiliations
  • 1Department of Medicine, University of California, San Francisco
  • 2Division of Gastroenterology, Department of Medicine, University of California, San Francisco
JAMA Intern Med. 2019;179(9):1272-1273. doi:10.1001/jamainternmed.2019.2244

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of diseases in which excess fat deposits in the liver (steatosis, NAFL) are separate from but can progress to inflammation and fibrosis (nonalcoholic steatohepatitis, NASH), fibrosis, and cirrhosis. Nonalcoholic fatty liver disease has become a major public health issue, affecting about 25% of adults worldwide and two-thirds of adults with obesity.1 Hepatocellular carcinoma associated with NAFLD increased 10-fold between 2000 and 2010, and trends suggest that NAFLD will emerge as the leading cause of end-stage liver disease in the coming decades.2 Beyond liver disease, patients with NAFLD are at significant risk of cardiovascular morbidity and mortality.3

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words